734 results about "Pharmacometrics" patented technology

A computer-implemented system for personalized health optimization constructs a confidence-weighted personal health knowledge graph (PHKG) from heterogeneous data, including wearable sensors, medical devices, lab results, medication logs, and conversational inputs. A multi-stage causal-inference stack identifies modifiable drivers of outcomes using layered methods (e.g., MI, GAM, Neural Granger, DAG-GNN), and simulates candidate interventions. A recommendation engine ranks lifestyle or pharmacologic actions using a benefit-to-friction score, selecting a personalized intervention aligned with user readiness and clinical safety constraints. Interventions may include a minimum effective dose (MED), optimal level, adaptive low-dose, or behavioral challenge. Optional modules include reinforcement learning for timing adaptation and privacy-preserving on-device inference. The system operates across domains including metabolic, cardiovascular, renal, sleep, stress, and medication response, enabling cross-condition synergy evaluation. The architecture is modular, supports runtime plug-in targets, and adapts in real time with or without continuous clinical oversight, depending on deployment.

Veterinary pharmaceutical compositions for direct systemic introduction, also known as DSI pharmaceutical compositions. One veterinary pharmaceutical composition for direct systemic introduction includes about 10-17 dry mass % bovine gelatin; about 10-17 dry mass % mannitol; about 0-1 dry mass % of a surfactant; and about 65-80 dry mass % of the active pharmaceutical ingredient which is a proton pump inhibitor. A method of manufacturing a veterinary pharmaceutical composition for direct systemic introduction includes combining one or more pharmacologically inactive compounds to form a first solution; using one or more surfactants to form a second solution; adding an active pharmaceutical ingredient to the second solution to form a first mixture; adding the first solution to the first mixture to form a pre-formulation; freezing the pre-formulation; and lyophilizing the pre-formulation.

Compounds of formula (II) and formula (I) which are inhibitors of QPCTL and QPCT: (II) and (I) are provided herein. Also provided are pharmaceutical compositions containing this compound, as well as compounds for use in methods of treating cancer, neurodegenerative, inflammatory or autoimmune diseases. Exemplary compounds are, for example, 3-(6-fluoropyridin-3-yl)-2-[4-(4-methyl-4H-1,2,4-triazol-3-yl)piperidin-1-yl]benzonitrile (Example 1): (1), and pharmacological data are provided. TIFF2025524039000368.tif70128

The present invention addresses the problem of providing a novel compound that has an OX2R agonist activity.　The present invention relates to a substituted sulfonamide compound which is represented by formula (I) or a pharmacologically acceptable salt thereof. A compound according to the present invention, or a pharmacologically acceptable salt thereof, has an agonist activity against OX2R, and is useful as, for example, a therapeutic agent for sleep disorders associated with OX2R (for example, narcolepsy, idiopathic hypersomnia, Kleine-Levin syndrome, hypersomnia associated with a physical disease, hypersomnia associated with a mental disease, hypersomnia associated with a drug or a substance, circadian rhythm sleep-wake disorders, insufficient sleep syndrome, and extended sleep).

A cosmetic containing (A) an alkali metal salt of an alkanoyl N-methyltaurine having an alkanoyl group having 8-20 carbon atoms, (B) a plant extract, (C) one or more compounds selected from the group consisting of compounds represented by general formula (1) and pharmacologically acceptable salts thereof, and (D) water (in general formula (1), R1, R3, R4 and R6 are each independently an alkyl group having 1-3 carbon atoms, R2 is an alkyl group having 1-3 carbon atoms, and R3 is an alkyl group having 1-3 carbon atoms; and R2 and R5 each independently represent a hydrogen atom or an alkyl group having 1-3 carbon atoms. ). # imgabs0 #

The invention pertains to the technical field of biomedical engineering and pharmacology and, without being limited thereto, specifically relates to a composition that enables the healing of full-thickness and chronic wounds (particularly in the foot region) observed in individuals suffering from diabetic disease.

A system and method are herein disclosed. The system and method use a generative AI agent to analyze and identify synergistic blends of natural compounds for combination therapies by leveraging an array of specialized modes to access data from a multitude of sources including patient medical history (including test results, drug history, and imaging) to improve the efficacy of compounds, including traditional medicine, in line with combination therapy principles, aimed at: enhanced efficacy, decreased toxicity, improved dosage, and reduced drug resistance. In this way, the generative AI agent determines cross-therapeutic similarities and / or dissimilarities between pharmaceutical, naturopathic, homeopathic, and nutraceutical compounds along a plurality of compound property vectors such as efficiency, efficacy, toxicity, effects, side-effects, chemistry, pharmacology, pharmacokinetics, mechanisms of action, and pharmacodynamics, thereby enabling the proposition of cross-disciplinary and transdisciplinary therapeutic analyses and the identification of synergistic effects in combination therapies.

The invention discloses a traditional Chinese medicine composition for treating skin diseases and a preparation method of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 6-12 parts of radix notoginseng, 8-15 parts of radix salviae miltiorrhizae, 10-20 parts of rhizoma chuanxiong, 8-15 parts of rhizoma curcumae longae, 15-35 parts of radix angelicae sinensis, 3-8 parts of sandalwood, 3-8 parts of fructus aurantii immaturus, 40-60 parts of ramulus cinnamomi, 8-15 parts of rhizoma corydalis, 8-15 parts of rhizoma curcumae, 2-5 parts of flos carthami, 5-12 parts of radix puerariae, 8-15 parts of radix rehmanniae, 3-8 parts of pericarpium citri reticulatae and 8-15 parts of spica prunellae. The traditional Chinese medicine composition is prepared from 3-8 parts of radix trichosanthis, 15-35 parts of tribulus terrestris, 15-35 parts of cicada slough, 5-12 parts of stiff silkworm and 8-15 parts of rhizoma drynariae. According to a multi-target collaborative mechanism, network pharmacology proves that 12 pathological pathways such as IL-17A and the like can be regulated and controlled, and the TNF-alpha inhibition rate is 89% and the barrier repair speed is increased by 2.3 times through key component combination. According to a transdermal synergistic technology, the specific surface area of the medicine reaches 8.5 m < 2 > / g through superfine grinding, a Franz test shows that the penetration amount of tanshinone is increased by 3.7 times, and the onset time is shortened to 8.3 minutes. Dual scar regulation and control: the thickness of scars in 12 weeks is reduced by half through TGF-beta3 up-regulation and alpha-SMA inhibition, and the collagen order degree is improved by 3.2 times.

The invention provides a micro-fluidic organ chip for three-dimensional cell culture. The micro-fluidic organ chip comprises a cell model loading and culturing unit, a liquid inflow-outflow unit with height difference, and an embedded inverted cone compression ring sealing unit, the cell model loading and culturing unit is constructed by overlapping at least three layers of chips up and down; and the liquid inflow-outflow unit with the height difference is constructed and formed by respectively forming liquid circulation holes which are hermetically connected through the embedded inverted conical compression ring sealing unit on at least three layers of chips. According to the invention, the cell culture space is expanded through the cell model loading and culture unit, high compatibility of cell culture is realized, and the problem of non-uniform concentration of a test substance is eliminated through the liquid inflow-outflow unit with height difference; and high-reliability miniaturized sealing design is realized through the embedded inverted cone pressing ring sealing unit, and the device can be widely applied to culture of cell models and test substance treatment and effect index detection taking toxicological and pharmacological researches as target scenes.

The application provides application of grass aconite in preparation of anti-epilepsy drugs and a mechanism analysis method, relates to the technical field of anti-epilepsy drugs, and discloses a "drug active ingredient-key target point-disease-pathway" network diagram of the grass aconite anti-epilepsy by starting from the chemical structure of the effective component of the grass aconite, applying network pharmacology and molecular docking technology, revealing how the active component of the grass aconite plays the drug efficacy through "multi-target point, multi-pathway and multi-pathway" combined regulation, predicting the anti-epilepsy target point and mechanism of the grass aconite, and providing certain theoretical reference for research and development of the grass aconite as an anti-epilepsy drug and a functional food.

The invention provides a method for predicting microorganism-drug interaction through a double hypergraph contrast learning framework based on hierarchical attention, and solves the problems that the graph structure is simple, the interpretable analysis is increased, and the prediction precision is improved. The method consists of three modules: S1, data preprocessing: carrying out nonlinear fusion on similarity data of microorganisms and drugs to obtain comprehensive similarity of the microorganisms and the drugs, and forming a double hypergraph by combining an original incidence matrix and the comprehensive similarity with KNN and K-means algorithms; s2, feature extraction: sending the double-hypergraph obtained in the step S1 into a hierarchical attention and hypergraph convolutional network to obtain feature embedding, updating features based on comparison learning of the double-hypergraph, and fusing the double-hypergraph features through an integration network. And S3, result prediction: mapping the microorganism and drug characteristics obtained in the step S2 by using a full connection layer to obtain final characteristics, and performing dot product to obtain a prediction score. And outputting the obtained prediction score in combination with specific literature verification and a network pharmacology verification model.

The invention discloses an application of a pharmaceutical composition of erianin (ERI) and sorafenib (SOR) in preparation of an anti-liver cancer drug. The invention further discloses a pharmaceutical composition which comprises ERI and SOR, and the specific molar ratio of ERI to SOR is optimized and determined through an in-vitro experiment. The composition is developed based on multi-mode screening (network pharmacology prediction, molecular docking and molecular dynamics simulation) of STAT3 targets, and in-vitro experiments prove that the composition has synergistic anti-tumor activity and can be used for preparing anti-liver cancer drugs. The invention further discloses a development method of the ERI-SOR composition integrated with multi-mode computational simulation. Experiments prove that ERI and SOR both show a remarkable synergistic effect (combination index (CI) lt, 1) at the concentration of 0.5-16 [mu] M, CI at the optimal ratio (1: 1, 4 [mu] M + 4 [mu] M) reaches 0.617, the cell proliferation inhibition effect is remarkable compared with that of a single drug, and the excellent synergistic effect is shown.

The present invention addresses the problem of providing a novel compound that has OX2R agonist activity.　The present invention relates to a substituted sulfonamide macrocyclic compound represented by formula (I) or a pharmacologically acceptable salt thereof. This compound, or a pharmacologically acceptable salt thereof, has agonist activity against OX2R, and is useful as a treatment agent, etc., for sleep disorders involving OX2R (e.g., narcolepsy, idiopathic hypersomnia, Kleine-Levin syndrome, hypersomnia associated with a physical disease, hypersomnia associated with a mental disease, hypersomnia associated with a drug or a substance, circadian rhythm sleep-wake disorder, insufficient sleep syndrome, and extended sleep).

The invention provides a loxoprofen sodium double-release capsule micro-tablet and a preparation method of the loxoprofen sodium double-release capsule micro-tablet. Through the synergistic effect of the quick-release micro-tablet and the sustained-release micro-tablet, the quick-release micro-tablet can realize quick release and absorption, and the sustained-release micro-tablet can maintain relatively stable blood concentration for a long time. The administration frequency is reduced, the coordination of the postprandial administration requirement and the dietary habit is ensured, and the occurrence of gastrointestinal tract adverse reactions is reduced. The preparation provided by the invention conforms to the dosage form design of the hour pharmacology, can quickly take effect through administration twice every day, can maintain the blood concentration in the high-incidence time period of night diseases, avoids the disadvantage of taking medicine after meal when the night diseases attack, guarantees the sleep quality, and improves the overall treatment effect. The micro tablet is small in size and easy to swallow, and the medication compliance of patients with dysphagia is obviously improved. Through dosage form design and improvement, unmet clinical requirements are expected to be met by virtue of obvious advantages of the traditional Chinese medicine composition.

The invention relates to the technical field of biomedical engineering and pharmacology and relates to, but is not limited to, a method for the composition and production of a wound dressing for the healing of complete and chronic skin wounds.

The invention discloses a pseudomonas aeruginosa InA protein and application thereof, and relates to the technical field of biological detection, the InA protein is InAS2, InAAP41 or InAS8, the amino acid sequences of the InA protein are respectively shown as SEQ ID NO.1-3, and the nucleotide sequences for coding the InAS2, the InAAP41 and the InAS8 are shown as SEQ ID NO.4-6. Compared with the prior art, the InA protein can improve the solubility of target protein, in addition, the InA protein and pseudomonas aeruginosa immune protein also have ultrahigh affinity, a biosensing chip with regeneration reversibility is developed based on the InA protein, the chip can capture fusion protein with the InA protein, and the biosensing chip has the advantages that the biosensing chip can be used as a biosensing chip with regeneration reversibility, so that the biosensing chip can be applied to biosensing of pseudomonas aeruginosa. The chip can be used for detecting the affinity between the fusion protein with the InA tag and a candidate drug, drug screening is realized, and meanwhile, the protein-drug affinity kinetics detected by the chip can also be used for pharmacological research of drugs.

The invention belongs to the field of immunology and pharmacology, and particularly relates to a small-molecule inhibitor as well as a preparation method and application thereof. The small-molecule inhibitor has a structure as shown in a formula (1). The small-molecule inhibitor with a specific structure provided by the invention not only can specifically target C9, but also has high binding affinity with C9, can play an efficient complement inhibition activity role, effectively blocks the formation of a membrane attack complex (MAC), reduces the attack of the MAC on normal cells, relieves immune injury and inflammatory response caused by the attack, and has a good application prospect. Therefore, a new strategy is provided for research and development of medicines for treating various complement-mediated diseases. # imgabs0 #

The invention relates to the technical field of traditional Chinese medicines, and discloses application of an active ingredient of shiny-leaved yellowhorn leaves in preparation of a medicine for treating hyperuricemia. The xanthoceras sorbifolia leaf active ingredients comprise quercitrin, rutin and myricetin; the content of quercitrin is 0.2508 mg / g to 0.6719 mg / g, the content of rutin is 0.6707 mg / g to 1.5831 mg / g, and the content of myricetin is 0.8002 mg / g to 3.4858 mg / g. According to the invention, myricetin, quercitrin and rutin are determined as core effective substances of shiny-leaved yellowhorn leaves for treating hyperuricemia for the first time; the multi-target and multi-channel action mechanism is disclosed; meanwhile, network pharmacological analysis shows that the three components have high connectivity in a network and jointly act on key targets such as XOD, ACE, AKR1B1 and TNF, it is prompted that the three components do not act singly, but play a treatment role through multi-target and multi-channel cooperation, the traditional'single target-single drug 'thinking is changed into a'multi-component-multi-target-multi-channel' system regulation mode, and the treatment effect is improved. A new thought is provided for comprehensive treatment of the hyperuricemia.

This invention relates to a traditional Chinese medicine composition for improving cancer-related fatigue, its preparation method, and its application. Belonging to the field of traditional Chinese medicine technology, it solves the technical problems of the lack of modern traditional Chinese medicine preparations for cancer-related fatigue and the lack of a systematic explanation of the pharmacological mechanism. The solution is: a traditional Chinese medicine composition for improving cancer-related fatigue, its preparation method, and its application, formulated according to the principles of principal, assistant, adjuvant, and guide herbs. The principal herbs are Astragalus membranaceus and Codonopsis pilosula; the assistant herbs are Angelica sinensis and Rehmannia glutinosa; the adjuvant herbs are Poria cocos, Citrus reticulata peel, and Ophiopogon japonicus; and the guide herb is Glycyrrhiza uralensis. By weight fraction, the principal herb is 10-18 parts, the assistant herbs are 8-14 parts, the adjuvant herbs are 8-14 parts, and the guide herb is 1-3 parts. The preparation method of the traditional Chinese medicine composition for improving cancer-related fatigue includes the following steps: 1) water extraction; 2) concentration; 3) spray drying; 4) sieving and mixing; 5) granulation; and 6) drying and packaging. Compared with the prior art, this invention has the advantages of convenient administration, stable efficacy, and a systematic explanation of the pharmacological mechanism.

The application belongs to the field of neuropharmacology and medicine, and particularly relates to application of taurine cholic acid in preparation of a drug for preventing or treating Alzheimer's disease. Through animal model experiment verification, the A beta lateral ventricle injection is used to prepare an AD mouse model, and after oral administration of TCA for 2 weeks, cognitive behavior and pathological indexes are significantly improved.

The invention discloses an application of DL-3-phenyllactic acid in treatment of cardiac mucinoma. Based on metabonomics, it is found that the level of endogenous DL-3-phenyllactic acid in serum of a patient is remarkably reduced, pharmacodynamic verification is conducted by means of a cardiac mucinoma tissue-derived cardiac mucinoma organ model of the patient, it is proved that DL-3-phenyllactic acid can inhibit proliferation of cardiac mucinoma organs in a dose-dependent mode, and the half inhibitory concentration IC50 value of DL-3-phenyllactic acid is 95.52 mu M. The DL-3-phenyllactic acid can inhibit proliferation of cardiac mucinoma organs in a dose-dependent mode. Network pharmacological analysis indicates that the drug action mechanism may involve key targets such as AKT1 and SRC. The invention discloses the therapeutic efficacy of the DL-3-phenyllactic acid on the cardiac mucinoma for the first time, and provides a solid preclinical experimental basis for developing the DL-3-phenyllactic acid into the medicine for treating the cardiac mucinoma. The invention has non-obvious and important clinical application value.

The invention provides a traditional Chinese medicine composition, a traditional Chinese medicine preparation, a preparation method and application, and particularly belongs to the technical field of traditional Chinese medicine. The invention provides a traditional Chinese medicine composition. The traditional Chinese medicine composition comprises the following components in parts by weight: 20-50 parts of parched white peony root, 8-15 parts of pawpaw, 10-20 parts of radix clematidis, 20-40 parts of caulis spatholobi, 5-12 parts of honey-fried licorice root, 10-20 parts of fructus broussonetiae, 10-20 parts of radix cyathulae and 5-12 parts of cassia twig. The traditional Chinese medicine composition has great potential in the aspects of treating kOA and inhibiting osteophyte formation, and can be used for improving kOA cartilage injury. Through in-vitro experiments, network pharmacology and in-vivo experiments, the curative effect of XBD in treating kOA and the effect of XBD in inhibiting osteophyte formation are verified, it is proved that XBD has a regulation effect on cartilage degeneration and osteophyte formation, and an important thought is provided for developing innovative drugs with cartilage protection and abnormal osteophyte formation inhibition functions.

The invention discloses a coumarin-thiosemicarbazide compound and application of the coumarin-thiosemicarbazide compound. The preparation method comprises the following steps: firstly, synthesizing a coumarin-thiosemicarbazide derivative, and carrying out in-vitro antioxidant activity screening to obtain preferable derivatives 4g and 4i; analyzing an antioxidant action target based on network pharmacology and molecular docking, and performing intersection mapping on the action target and the antioxidant target of the compounds 4g and 4i to obtain a common target; constructing a PPI interaction network, and screening to obtain potential core targets; carrying out GO function and KEGG pathway enrichment analysis on the core target spot to obtain a related biological process and signal pathway; and carrying out molecular docking operation on the key target spot and compounds 4g and 4i to verify the binding capacity of the compounds and the target spot. Potential antioxidant targets and modern biological mechanisms of the derivatives 4g and 4i are preliminarily revealed by using a network pharmacology method, and important guidance and basis are provided for development of antioxidant drugs.

The utility model relates to the technical field of mouse weighing devices, and discloses a mouse weighing device for pharmacological experiments, which comprises an electronic scale, the upper end of the electronic scale is fixedly connected with a scale pan, the interior of the scale pan is provided with a placing seat, the upper end of the scale pan is provided with a fixing assembly, the inner wall of the placing seat is provided with a limiting groove, and the fixing assembly is provided with a fixing assembly. The fixing assembly comprises a motor, and the output end of the motor is fixedly connected with a bidirectional lead screw. The motor drives the two-way lead screws to rotate and drives the belt pulley to rotate, so that the transmission belt drives the other belt pulley, and therefore, the two two-way lead screws rotate, the nut seat is driven to move, and the arc-shaped plates move close to each other until the arc-shaped soft cushion is in contact with the body of a mouse; the clamping pressure is buffered through the buffer springs, the mouse is prevented from being hurt due to too large pressure, the mouse is fixed through the four arc-shaped soft cushions, the mouse fixing effect is improved, and the experiment accuracy and efficiency are improved.

The invention relates to the technical field of medical supplies, in particular to a wound repair medical dressing containing glycosylglycerol, and a dressing solution for the wound repair medical dressing comprises the following raw materials: carbomer 940, medical glycerol, glycosylglycerol, sodium hyaluronate, purified water, 1, 2-hexanediol, 1, 3-butanediol and a pharmaceutical adjuvant sodium hydroxide. The dressing is extruded to a skin wound surface or an affected part to form a thin film structure, a physical barrier is formed, the wound surface or the affected part is isolated from the external environment, the wound surface is protected from being polluted by the external environment, a microenvironment is provided for non-chronic wound surface healing, a protective layer is formed on the surface of the wound surface, the physical barrier effect is achieved, and the wound surface is protected. The dressing is used for nursing superficial wounds such as small wounds, scratches and incisions and surrounding skin; the contained components do not have pharmacological effects and cannot be absorbed by a human body.

A technique is provided for identifying correct or sufficient doses in a patient being treated with a drug for a neurological deviation condition. A method may include performing a plurality of fright response tests on a user, each test utilizing a device having a camera, a display, and optionally a speaker, and each test occurring at a different time after the user has been administered a medicament. The method may include receiving a plurality of images of at least one eye of the user from a camera during each test, and then calculating a magnitude of eyelid closure based on each image. The method may include determining a value of a correlation between a predetermined plasma concentration of the drug and the determined amplitude, and then determining whether a correct or sufficient dose has been reached based on the value of the correlation.

The invention relates to the fields of pharmacology and molecular biology, and discloses an autophagy inhibitory polypeptide competitively combined with an LIR docking site of an autophagy-related protein LC3 and application of the autophagy inhibitory polypeptide. Through molecular docking simulation, through LIR docking sites of targeted LC3 protein, 794 bioactive polypeptides which can be combined are screened out. Functional result analysis shows that peptide 3 #, peptide 4 # and peptide 5 # are competitively combined with LIR docking sites of the LC3 protein, so that formation of autophagy vesicles is inhibited in a targeted manner, and proliferation and survival of autophagy-dependent pancreatic cancer cells are effectively inhibited; the strategy is combined with chemotherapeutic drugs to show a synergistic effect, and the pancreatic cancer resisting curative effect is remarkably enhanced.

The invention relates to organic chemistry, pharmacology and medicine and concerns novel peptides characterized in that they exhibit antitumour activity, which can be used, in particular, for the prophylaxis and treatment of neoplastic diseases in a subject. In addition, the present invention also includes the use of the claimed peptides for the treatment of neoplastic diseases, as well as pharmaceutical compositions for the treatment of neoplastic diseases which contain the claimed peptides.

The present invention refers to compounds of formula (I). The present invention also relates to compounds of formula (I) for use as G Protein coupled Receptor 139 (GPR139) antagonists in methods of medical treatment of e.g. depression, Alzheimer's disease, schizophrenia, drug addiction, sleep disorders, pain, and attention deficit hyperactivity disorder. Exemplary compounds are e.g. 3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds. The present description discloses the synthesis and characterisation of exemplary compounds, pharmacological data thereof, as well as exemplary tablet formulations comprising the compounds of the invention (e.g. page 83 to page 110; examples 1 to 33; reference example 1; test examples 1 and 2; tables 1 to 4).

The invention discloses a traditional Chinese medicine composition for preventing and treating alcoholic liver injury, and relates to the technical field of traditional Chinese medicines, and the traditional Chinese medicine composition is prepared from the following raw materials in parts by mass: 10 to 15 parts of radix puerariae, 6 to 12 parts of semen hoveniae, 6 to 10 parts of radix angelicae sinensis, 6 to 10 parts of fructus lycii and 2 to 5 parts of liquorice root. Based on the treatment rule of'dispelling effects of alcohol, regulating qi and blood and tonifying liver and kidney 'in traditional Chinese medicine, medicinal and edible traditional Chinese medicines such as radix puerariae and hovenia dulcis thunb are primarily screened, and meanwhile, a'multi-target synergistic mechanism' predicted by network pharmacology is constructed and converted into a quantifiable treatment effect. The experimental data not only verifies the key pathway of GO / KEGG enrichment, but also systematically verifies the compound liver protection effect through multi-scale indexes such as visceral organ indexes, serum enzymology, histopathology and the like. The research not only provides a novel compound with a clear mechanism for ALD, but also demonstrates the feasibility of driving the precise design of a traditional Chinese medicine compound by network pharmacology, and lays a methodological foundation for modern development of medicinal and edible resources.